JIC
IRD

Johnson Investment Counsel’s Opus Genetics IRD Stock Holding History

Johnson Investment Counsel’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20,000
Closed -$40.2K – 903
2025
Q4 		$40.2K Buy
+20,000
New +$40.6K ﹤0.01% 785

Other funds holding IRD

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Johnson Investment Counsel's IRD Position: Q1 2026 in Review

Johnson Investment Counsel sold out of Opus Genetics (IRD) in Q1 2026, closing a stake of 20,000 shares — an estimated $40.2K sold.

Johnson Investment Counsel first reported a position in IRD in Q4 2025 and held it in 1 quarter. The position peaked at $40.2K in Q4 2025. 79 funds tracked by Wall St. Rank hold IRD as of Q1 2026.

  • Johnson Investment Counsel reported no remaining Opus Genetics position as of Q1 2026 after selling out during the quarter.
  • Johnson Investment Counsel sold 20,000 Opus Genetics shares in Q1 2026, an estimated $40.2K.
  • Johnson Investment Counsel first reported a position in Opus Genetics in Q4 2025 and held it in 1 quarter.
  • Johnson Investment Counsel's Opus Genetics position peaked at $40.2K in Q4 2025.
  • 79 funds tracked by Wall St. Rank held Opus Genetics as of Q1 2026.

Based on Johnson Investment Counsel's 13F filing for Q1 2026, filed 4 May 2026.